Immunotherapy sensitive advanced or metastatic cancer

Clinical criteria:

• Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for the condition which treatment was commenced for.

The stated maximum amount in this listing is 360 mg however alternative dosing schedules may be prescribed in a quantity up to this amount, but need not be this amount for every cancer type.